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Brain metastases and subtypes of breast
cancer
Breast cancer metastases to the central nervous system (CNS)
include the clinically distinct situations of multiple brain
metastases (78%), solitary brain metastasis (14%), and
leptomeningeal metastases (8%) [1, 2]. CNS metastases occur
in 10%–16% of stage IV patients while they are found in
30% of patients in autopsy series [1]. In populations of early
breast cancer patients treated on adjuvant trials, CNS-
recurrence rates of 3%–6% have been observed [3, 4]. CNS
recurrences have consistently been found to occur with
increased frequency in younger and premenopausal patients
as well as in estrogen receptor (ER)-negative and/or
progesterone receptor (PgR)-negative cancers. While some
series found correlations of CNS recurrences with nodal
status, high tumor grade, tumor size, and HER2 status [4],
other series have described associations with high S phase,
aneuploidy, and p53 positivity [3]. There was no correlation
between CNS recurrences and type of adjuvant systemic
treatments [3, 5]. Several groups have reported an increased
frequency of CNS recurrence in patients with lung metastases
[4, 6].
In the April issue of Annals of Oncology, a series of 679
‘triple receptor-negative’ (ER negative, PgR negative, and HER2
negative) early breast cancer patients treated at the M. D.
Anderson Cancer Center in Houston from 1980 to 2006 are
described, in which 42 (6.2%) developed brain metastases after
a median follow-up of 26.9 months [7]. Similar findings were
reported at the 2008 American Society of Clinical Oncology
meeting from Wiesbaden, Germany. Of the 338 patients with
triple receptor-negative breast cancer treated from 1989 to
2006, cerebral metastases developed in 19 (5.6%) [8]. In the
German study, triple receptor-negative breast cancer brain
metastases developed earlier than in other receptor subtypes,
occurring at a median interval of 22 months after primary
diagnosis versus 51 months for all other subtypes. In addition,
both groups have reported that overall survival of patients with
triple receptor-negative tumors who develop CNS metastases is
particularly dismal, with median survival times of 2.9 and
4 months, respectively [7, 8].
How can we put these findings into context, what is new
about them? And what are the possible implications of these
findings, for clinical management and for research?
Currently, clinical and translational research in breast cancer
concentrates on dissecting the heterogeneity of the disease into
different subtypes. Gene expression profiles classify breast
cancers into luminal, basal and HER2-positive subtypes with
clearly different prognostic significance [9]. Clinical scientists
and pathologists have approximated these molecularly defined
categories by using expression of ERs and PgRs as well as
expression and/or amplification of HER2 which are readily
available predictive factors [10, 11]. In this approximation,
the new category of triple receptor-negative breast cancer has
been created which comprises 15% of all breast cancers and
85% of basal-type tumors. Nevertheless, the category of
triple-negative breast cancer is by no means a homogeneous
group, and even when using additional ‘basal’ markers such as
CK5/6, EGFR, P-cadherin, and/or lymphocyte infiltration,
overlap with basal-like tumors remains incomplete [12].
Additional molecular features characterizing smaller
subgroups of triple-negative cancers are p53 mutations,
BRCA1 mutations, and others. Obviously, all these
associations deserve and need additional investigation. For the
time being, a word of caution seems appropriate; while ‘triple
negative’ is a handy designation for clinicians, it is an
unsatisfactory category in at least three ways: it is not
a biologically homogeneous subgroup, it does not help to
select a particular treatment (it only allows to avoid endocrine
and HER2-directed treatments), and its prognosis overall is
worse. While a subset of patients with triple-negative breast
cancer can be cured with the addition of adjuvant
chemotherapy, others relapse quickly despite such treatment
[13]. It is not uncommon that patients who hear of their
triple-negative cancer and particularly those who read about it
on the Internet return to their oncologist with ‘triple
unhappiness’. We have previously known that ER-negative
and PgR-negative breast cancers are more likely to develop
CNS metastases [3, 4]. Now, we have learned that in triple-
negative breast cancer they appear particularly early and have
a particularly dismal prognosis [7, 8].
There is considerably more information available about CNS
metastases in HER2-positive disease which should be included
into this discussion. Recently, the M. D. Anderson group has
published a large retrospective analysis of breast cancer patients
with CNS metastases and known HER2 status [14]. A total of
598 patients from 1994 to 2006 were included, and 280 HER2-
positive patients were compared with 318 HER2-negative
patients. Time to brain metastasis and especially time from
brain metastasis to death were longer for trastuzumab-treated
HER2-positive disease (11.6 months) when compared with
either HER2-positive disease not treated with trastuzumab
(6.1 months) or HER2-negative disease (6.3 months).
Several other publications have reported high rates of CNS
recurrences in HER2-positive breast cancer patients treated
with trastuzumab [15–17]. Typically, CNS metastases become
manifest, while systemic metastases are still responding to
trastuzumab-containing regimens. This type of mixed response
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is commonly attributed to the fact that trastuzumab is not able
to cross the blood–brain barrier and appear in the cerebrospinal
fluid [18]. Very recently, it has been reported that trastuzumab
can penetrate into breast cancer CNS metastases as measured
by PET scanning [19]. In contrast to the mAb trastuzumab
(with a molecular mass of 145 kDa), the anti-HER2 and anti-
HER1 small-molecule tyrosine kinase inhibitor lapatinib (581
Da) is able to cross the intact blood–brain barrier. Lapatinib
has been shown to have some clinical activity in the treatment
of brain metastases from HER2-positive disease [20] and to
reduce the likelihood of CNS metastases in a large randomized
study in advanced disease comparing capecitabine with or
without lapatinib [21]. These and many other studies have
generated a lot of enthusiasm because here is evidence that
treatment decisions for metastatic disease should consider the
site of metastasis. Nevertheless, the optimal approach remains
uncertain in the case of a patient with HER2-positive disease
who develops multiple CNS metastases while responding
systemically to a trastuzumab-containing regimen. Should such
a patient receive whole brain radiotherapy (WBRT) and
continue systemic treatment including trastuzumab (leaving
the possibility of future use of lapatinib for a second CNS
progression), or should the patient receive WBRT and be
switched to the lapatinib–capecitabine combination
immediately [22]? Based on reports of increased survival after
CNS metastases in HER2-positive patients treated with
trastuzumab, the first option continues to be a reasonable
choice [14, 23].
CNS metastases constitute a difficult clinical problem and are
feared by patients and clinicians alike. They are usually
accompanied by neurological deficits and are considered to be
the main cause of death in more than half of the patients [5].
Treatment options include steroids (dexamethasone), surgical
excision of solitary metastases, stereotactic radiosurgery for
small (<3 cm) lesions not amenable to surgery, and WBRT.
While the optimal combination of these options has clearly
improved the prognosis, the median survival time of patients
with CNS metastases is 4–6 months, and only 20%–40% of
patients are alive at 1 year [5, 14]. New approaches are
desperately needed. One possibility would be prophylactic
cranial irradiation (PCI) as is routinely used for small-cell lung
cancer. Would it be possible to define a subgroup of patients
with a very high risk of CNS relapse who could potentially
benefit from PCI? Unfortunately, the only data available do not
support this approach. A series of 155 patients with metastatic
disease screened for occult CNS involvement found 23 (14.8%)
patients with occult disease [24]. Although the prognosis for
these patients was reduced compared with those without occult
CNS disease, there was no evidence that earlier treatment of
CNS disease was beneficial. In 2006, the NCI launched an early
CNS metastasis detection trial comparing 4-monthly to 12-
monthly MRIs in HER2-positive stage IV breast cancer
patients. Other trials are investigating temozolamide, lapatinib,
and other approaches to prevent brain metastases. These trials
are conveniently listed at www.BrainMetsBC.org. It is our duty
to intensify research in this area. One aspect involving many
clinical researchers around the world is the subproject
investigations of CNS recurrences in the large adjuvant trials
for HER2-positive disease such as the HERA trial and the
ALTTO trial. For the first time, these projects analyze in
adequate detail the type of CNS recurrence and their
relationship to systemic disease and to various treatments
including trastuzumab and lapatinib. Similarly, all the
randomized adjuvant trials conducted in HER2-positive disease
with trastuzumab and/or lapatinib should have rigorous and
special documentation of CNS recurrences.
At the same time, research of brain metastases in animal
models has gained considerable momentum. Starting with
human breast cancer cells harvested from a pleural effusion and
injecting them into the left cardiac ventricle of nude mice,
harvesting brain metastases and reinjecting them again into
nude mice, it has been possible to establish mouse model
systems of brain metastases [25]. Using these models,
mechanistic studies of the roles of angiogenesis, energy
metabolism, HER2 and Stat3 signaling pathways, as well as of
metastasis dormancy are being carried out. For example,
a brain tropic subline of the human MDA-MB-231 breast
cancer cell line (231BR) was transfected with low or high
amounts of HER2. Compared with the parental line, the HER2
transfectants yielded threefold greater numbers of large brain
metastases [26]. This result shows that the high incidence of
brain metastases in HER2-positive disease probably has
a biologic basis and is not only due to the pharmacokinetic fact
that trastuzumab cannot penetrate the intact blood–brain
barrier.
Investigations into the molecular basis of metastasis to bone
and lung in breast cancer have been very successful [27]. Genes
used for initiation, progression, and virulence of metastasis and
genes for interactions between tumor cells and their stroma
have been described [28]. The seed and soil hypothesis has been
developed into a conceptual framework for testing the cellular
processes involved in metastatic progression. Joan Massague´’s
laboratory at Memorial Sloan Kettering has found that a lung-
metastasis signature (but not a bone-metastasis signature)
shows significant overlap with the brain-metastasis signature
[29]. The hypothesis is that breast cancer cells invade the brain
through functions provided by lung extravasation genes (plus
functions provided by unique blood–brain barrier
extravasation genes). This research finding corresponds well
with the clinical observation that patients with lung metastases
have an increased risk for the development of brain metastases.
It is encouraging to note that progress in basic science is linking
with clinical investigation.
B. C. Pestalozzi
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